Palo Alto, California, USA, and Suzhou, China, November 15, 2026
Innovent Biologics has announced that its immunotherapy Zybrivo® (sintilimab) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending its use in combination with chemotherapy as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer (NSCLC). This regulatory milestone represents an important step in Innovent’s international expansion and could introduce an additional treatment option for eligible patients across Europe if the European Commission grants final marketing authorisation. The recommendation is supported by clinical evidence from the Phase 3 ORIENT-11 trial, which evaluated sintilimab combined with pemetrexed and platinum-based chemotherapy in patients with locally advanced, metastatic or recurrent non-squamous NSCLC. The positive opinion marks Innovent’s first European regulatory milestone and highlights the growing international development of innovative cancer immunotherapies. The company aims to expand access to its oncology portfolio by advancing clinical research and regulatory submissions in major global markets.
CHMP Recommends Zybrivo for First-Line Lung Cancer Treatment
The positive CHMP opinion recommends Zybrivo (sintilimab) in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of eligible adults with advanced non-squamous NSCLC. The recommended population includes patients with locally advanced disease who are not candidates for curative-intent surgery or chemoradiation, as well as those with metastatic disease. The recommendation applies to patients without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. The European regulatory review was based on evidence demonstrating the clinical benefits of combining PD-1 immunotherapy with established chemotherapy agents. Following the positive CHMP opinion, the European Commission is expected to make a final decision on marketing authorisation in the coming months. If approved, the authorisation would cover all 27 European Union member states, together with Iceland, Norway and Liechtenstein. This would represent a significant commercial and regulatory opportunity for Innovent while potentially expanding treatment choices for patients with advanced lung cancer. However, the CHMP recommendation itself does not constitute final marketing approval.
Phase 3 ORIENT-11 Trial Demonstrates Clinical Benefits
The recommendation is supported by results from the Phase 3 ORIENT-11 clinical trial (NCT03607539), a randomised, multicentre, double-blind, placebo-controlled study involving 397 adult patients with locally advanced, metastatic or recurrent non-squamous NSCLC. Participants were assigned in a 2:1 ratio to receive either sintilimab or placebo, each in combination with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), assessed through blinded independent radiological review. The findings demonstrated that sintilimab combined with chemotherapy reduced the risk of disease progression or death by 52% compared with placebo plus chemotherapy. Median progression-free survival reached 8.9 months compared with 5.0 months in the control group. The combination also demonstrated a 35% reduction in the risk of death, with median overall survival reaching 24.2 months compared with 16.8 months for patients receiving placebo and chemotherapy. These results support the potential clinical value of adding sintilimab to standard chemotherapy in the first-line treatment setting. The reported safety profile was consistent with the known safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified. The results provide the clinical foundation for the European regulatory recommendation.
PD-1 Immunotherapy Strengthens Innovent’s Oncology Portfolio
Sintilimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody designed to target programmed cell death protein 1 (PD-1), an immune checkpoint protein involved in regulating immune responses. By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, sintilimab helps restore the immune system’s ability to recognise and attack cancer cells. This mechanism makes PD-1 inhibitors an important class of medicines in modern cancer immunotherapy. Sintilimab has already received approvals in China for multiple cancer indications, including different forms of lung cancer, hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, oesophageal squamous cell carcinoma, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin’s lymphoma. According to Innovent, approximately 3 million patients in China have received sintilimab. The positive CHMP opinion therefore represents an important step in extending the medicine’s regulatory reach beyond its established domestic market. Innovent continues to develop treatments across oncology, autoimmune, cardiovascular, metabolic and ophthalmic diseases, supported by collaborations with international pharmaceutical companies. The European regulatory milestone highlights the company’s commitment to advancing innovative biopharmaceutical products through global clinical development. If final approval is granted, Zybrivo could become an additional first-line immunotherapy option for eligible adults with advanced non-squamous NSCLC in Europe, strengthening the treatment landscape for a major cancer indication.
Source: Innovent Biologics press release



